Compare MLGO & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLGO | LITS |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | China | United States |
| Employees | N/A | 4 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.4M | 40.8M |
| IPO Year | 2020 | N/A |
| Metric | MLGO | LITS |
|---|---|---|
| Price | $3.32 | $1.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 92.7K | ★ 285.6K |
| Earning Date | 03-27-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $87,132,230.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.91 | ★ N/A |
| Revenue Growth | ★ 6.21 | N/A |
| 52 Week Low | $0.50 | $0.95 |
| 52 Week High | $32.40 | $3.03 |
| Indicator | MLGO | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 38.11 | 47.25 |
| Support Level | $3.30 | $1.01 |
| Resistance Level | $4.53 | $1.16 |
| Average True Range (ATR) | 0.30 | 0.06 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 5.49 | 11.54 |
MicroAlgo Inc is divided into two segments: Central processing algorithm services & Intelligent chips and services. The majority is from the Central Processing Algorithm Services. which refers to a range of computing algorithms, analytical algorithms, recommendation algorithms, & acceleration algorithms. The businesses engaged in internet advertisement, game development, intelligent chip design, finance, retail, & logistics depend on the ability to process & analyze data with optimized computing software & hardware capable of handling the data workload. Intelligent chips and services revenues include revenues generated from the resale of intelligent chips. All of the Company's net revenues were generated in the PRC, Hong Kong, & Singapore, out of which the majority is from the PRC.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.